<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02984787</url>
  </required_header>
  <id_info>
    <org_study_id>Experiment20161201</org_study_id>
    <nct_id>NCT02984787</nct_id>
  </id_info>
  <brief_title>3D Versus 2D Laparoscopic Total Gastrectomy With Splenic Hilum Lymph Nodes Dissection</brief_title>
  <official_title>3D Versus 2D Laparoscopic Total Gastrectomy With Spleen-preserving Splenic Hilum Lymph Nodes Dissection for Advanced Proximal Gastric Cancer: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will perform a prospective randomized comparison between 3D and 2D
      laparoscopic total gastrectomy with splenic hilum lymph nodes dissection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized comparison of 3D and 2D laparoscopic surgery for advanced gastric
      cancer with spleen-preserving splenic hilum lymph nodes dissection will be performed, to
      evaluate the safety and feasibility for the extensive application of the novel 3D
      laparoscopic technique. The evaluation parameters are number of group No.10 lymph nodes
      harvested, perioperative clinical efficacy, postoperative life quality and 3-year survival
      and recurrence rates.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of splenic hilum lymph nodes harvested</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early complication rate</measure>
    <time_frame>30 days</time_frame>
    <description>The early complication rate is defined as the event observed during operation and within 30 days after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>Intraoperative</time_frame>
    <description>It will be assessed with the unit of &quot;minute&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative blood loss</measure>
    <time_frame>Intraoperative</time_frame>
    <description>It will be assessed with the unit of &quot;ml&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of splenic hilum lymph nodes dissection</measure>
    <time_frame>Intraoperative</time_frame>
    <description>It will be assessed with the unit of &quot;minute&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of total lymph nodes harvested</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Poster-operative recovery course</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first ambulation (unit of hour), flatus (unit of hour), liquid diet (unit of hour) and duration of hospital stay (unit of day) are used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>It will be assessed with questionnaire of &quot;WHO-QOL-100&quot; (WHO was short for world health organization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year disease free survival rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Splenic Hilum Lymph Nodes Dissection</condition>
  <arm_group>
    <arm_group_label>3D Laparoscopic total gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants including in the 3D laparoscopic total gastrectomy (3D-LTG) group will undergo 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2D Laparoscopic total gastrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants including in the 2D laparoscopic total gastrectomy (2D-LTG) group will undergo 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>3D Laparoscopic total gastrectomy</intervention_name>
    <description>When participants with advanced proximal gastric cancer are randomized in the 3D laparoscopic-assisted totalgastrectomy (3D-LTG) group, they will received 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection</description>
    <arm_group_label>3D Laparoscopic total gastrectomy</arm_group_label>
    <other_name>3D-LTG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>2D Laparoscopic total gastrectomy</intervention_name>
    <description>When participants with advanced proximal gastric cancer are randomized in the 2D laparoscopic-assisted totalgastrectomy (2D-LTG) group, they will received 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection</description>
    <arm_group_label>2D Laparoscopic total gastrectomy</arm_group_label>
    <other_name>2D-LTG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Primary proximal gastric adenocarcinoma confirmed pathologically by endoscopic biopsy;

          2. cT2-4aN0-3M0 at preoperative evaluation according to AJCC Cancer Staging Manual, 7th
             Edition.

          3. Eastern Cooperative Oncology Group (ECOG): 0 or 1;

          4. American Society of Anesthesiologists （ASA） score: Ⅰto Ⅲ;

          5. Written informed consent.

        Exclusion Criteria:

          1. Pregnant or breast-feeding women;

          2. Severe mental disorder;

          3. Previous upper abdominal surgery (except laparoscopic cholecystectomy);

          4. Previous gastrectomy, endoscopic mucosal resection, or endoscopic submucosal
             dissection;

          5. Enlarged or bulky regional lymph node diameter larger than 3 cm based on preoperative
             imaging;

          6. Other malignant disease within the past 5 years;

          7. Previous neoadjuvant chemotherapy or radiotherapy;

          8. Contraindication to general anesthesia (severe cardiac and/or pulmonary disease);

          9. Emergency surgery due to a complication (bleeding, obstruction, or perforation) caused
             by gastric cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>the Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongqing Xi, Master</last_name>
    <phone>86-13801290395</phone>
    <email>chenlinbj@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lin Chen</last_name>
      <phone>86-13801290395</phone>
      <email>chenlinbj@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2016</study_first_submitted>
  <study_first_submitted_qc>December 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2016</study_first_posted>
  <last_update_submitted>December 4, 2016</last_update_submitted>
  <last_update_submitted_qc>December 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Lin Chen</investigator_full_name>
    <investigator_title>Deputy Director</investigator_title>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>3D</keyword>
  <keyword>2D</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

